Natixis Advisors LLC Acquires 7,731 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Natixis Advisors LLC lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,382 shares of the medical equipment provider's stock after buying an additional 7,731 shares during the quarter. Natixis Advisors LLC's holdings in Zimmer Biomet were worth $7,540,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ZBH. CKW Financial Group lifted its position in shares of Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after acquiring an additional 100 shares in the last quarter. Romano Brothers AND Company lifted its holdings in Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock worth $1,000,000 after purchasing an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after purchasing an additional 102 shares during the period. M&T Bank Corp grew its holdings in Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after buying an additional 108 shares in the last quarter. Finally, Dakota Wealth Management increased its position in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after buying an additional 122 shares during the period. 88.89% of the stock is owned by institutional investors.

Remove Ads

Zimmer Biomet Trading Down 0.7 %

ZBH stock traded down $0.74 during midday trading on Tuesday, hitting $110.50. The company had a trading volume of 1,296,857 shares, compared to its average volume of 1,496,400. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The stock has a market cap of $22.00 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.95 and a beta of 1.04. The stock's 50 day moving average price is $106.86 and its 200 day moving average price is $106.86.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business earned $2.20 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZBH shares. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Finally, Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.